Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003667 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003667: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003667 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003667, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy with biological therapy may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy with or without biological therapy in treating patients who have newly diagnosed high-risk Ewing's sarcoma.
Interventions
- DRUG cyclophosphamide
- DRUG dexrazoxane hydrochloride
- DRUG doxorubicin hydrochloride
- DRUG vincristine sulfate
- DRUG disaccharide tripeptide glycerol dipalmitoyl
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Est. Completion | 2000-08 |
| Phase | Phase 2 |
What the finished NCT00003667 record still lists
NCT00003667 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003667 about?
NCT00003667 is a clinical study titled "Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy with biological therapy may kill more tumor cells....
What is the current status of trial NCT00003667?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-09. Estimated completion is 2000-08.
What interventions are being tested in trial NCT00003667?
The interventions under investigation include: cyclophosphamide (DRUG), dexrazoxane hydrochloride (DRUG), doxorubicin hydrochloride (DRUG), vincristine sulfate (DRUG), disaccharide tripeptide glycerol dipalmitoyl (DRUG).
Who is sponsoring clinical trial NCT00003667?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia